Abstract
Urinary incontinence and lower urinary tract dysfunction remain an important cause of morbidity, affecting at least 14% of women over the age of 30 years. Whilst the etiology and pathophysiology of detrusor instability remains to be elucidated drug therapy remains important in the management of women with the irritative symptoms of urgency, frequency and urge incontinence. The number of drugs which have been developed illustrates the point that none are ideal, often having systemic adverse effects limiting their therapeutic usage and affecting compliance. This review aims to assess the current pharmacological management of detrusor instability as well as examining recent progress in the development of new agents, some of which may prove to be efficacious.
MeSH terms
-
Adrenergic alpha-Antagonists / therapeutic use
-
Adrenergic beta-Agonists / therapeutic use
-
Antidepressive Agents, Tricyclic / therapeutic use
-
Calcium Channel Blockers / therapeutic use
-
Cholinergic Antagonists / therapeutic use
-
Cyclooxygenase Inhibitors / therapeutic use
-
Female
-
Humans
-
Muscular Diseases / drug therapy*
-
Muscular Diseases / physiopathology
-
Neurotoxins / therapeutic use
-
Parasympatholytics / therapeutic use
-
Potassium Channels / agonists
-
Potassium Channels / therapeutic use
-
Urologic Diseases / drug therapy*
-
Urologic Diseases / physiopathology
Substances
-
Adrenergic alpha-Antagonists
-
Adrenergic beta-Agonists
-
Antidepressive Agents, Tricyclic
-
Calcium Channel Blockers
-
Cholinergic Antagonists
-
Cyclooxygenase Inhibitors
-
Neurotoxins
-
Parasympatholytics
-
Potassium Channels